Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 9/20 | 0.41 |
| ▸ | NPY1R | P25929 | 6/20 | 0.41 |
| ▸ | BACE1 | P56817 | 5/20 | 0.41 |
| ▸ | NPY2R | P49146 | 4/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.41 |
| ▸ | CTSD | P07339 | 2/20 | 0.41 |
| ▸ | ECE1 | P42892 | 2/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.38 |
| ▸ | FURIN | P09958 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29524799 | 0.94 | BACE1 (0.42) | NPY4RNPY1RBACE1NPY2RNPY5R | |
| SCHEMBL9819635 | 0.92 | NPY4R (0.41) | NPY4RNPY1RBACE1NPY2RNPY5R | |
| SCHEMBL9819630 | 0.92 | NPY4R (0.41) | NPY4RNPY1RBACE1NPY2RNPY5R | |
| SCHEMBL30786591 | 0.92 | NPY4R (0.48) | NPY4RNPY1RBACE1NPY2RNPY5R | |
| SCHEMBL16432553 | 0.91 | NPY4R (0.48) | NPY4RNPY1RBACE1NPY2RNPY5R | |
| SCHEMBL29854189 | 0.91 | BACE1 (0.46) | NPY4RNPY1RBACE1NPY2RNPY5R | |
| SCHEMBL16432550 | 0.91 | NPY4R (0.48) | NPY4RNPY1RBACE1NPY2RNPY5R | |
| SCHEMBL31206359 | 0.91 | NPY4R (0.46) | NPY4RNPY1RBACE1NPY2RNPY5R | |
| SCHEMBL9852051 | 0.91 | NPY4R (0.42) | NPY4RNPY1RNPY2RNPY5RECE1 | |
| SCHEMBL29697038 | 0.91 | NPY4R (0.42) | NPY4RNPY1RNPY2RNPY5RECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10913770-B2 | Mertansine polypeptide conjugates | VISION GLOBAL HOLDINGS LIMITED (CN) | 2021-02-09 | — | — | US | disclosed |
| US-20200361988-A1 | MERTANSINE POLYPEPTIDE CONJUGATES | VISION GLOBAL HOLDINGS LIMITED (HK) | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361988-A1 | MERTANSINE POLYPEPTIDE CONJUGATES | NGLY1, ANPEP, VIP | NPY4R 896/4885NPY1R 939/4885BACE1 1723/4885 |
| US-10913770-B2 | Mertansine polypeptide conjugates | NGLY1, ANPEP, VIP | NPY4R 896/4885NPY1R 939/4885BACE1 1723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.